[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335966-105":59,"doc-detail-335966-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cabergoline-as-a-novel-strategy-for-post-pregnancy-breast-cancer-prevention-in-mice-and-human","Cabergoline as a Novel Strategy for Post-Pregnancy Breast Cancer Prevention in Mice and Human","","Post-pregnancy breast cancer presents poor prognosis and increasing later-life pregnancies amplify risk, creating a need for effective chemoprevention. Current approaches such as selective estrogen receptor modulators, aromatase inhibitors, and surgical options show limited efficacy and notable side effects. Cabergoline, a dopaminergic agonist, is reported to reduce post-pregnancy breast cancer risk in a Brca1/P53-deficient mouse model. Single-dose treatment delays tumor onset and lowers incidence, with early histology showing accelerated postlactational involution, increased apoptosis, and gene-expression changes linked to ion transport. Longer-term analyses reveal reduced ductal components, decreased epithelial proliferation, and fewer Brca1/P53 target cells, while RNA sequencing identifies expression shifts associated with diminished proliferation and altered mammary branching. These findings suggest cabergoline enhances pregnancy-mediated protection by potentiating postlactational involution, supported by a retrospective human cohort showing lower incidence among treated women compared with controls.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cabergoline-as-a-novel-strategy-for-post-pregnancy-breast-cancer-prevention-in-mice-and-human/335966/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cabergoline-as-a-novel-strategy-for-post-pregnancy-breast-cancer-prevention-in-mice-and-human/335966.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is post-pregnancy breast cancer prevention important?","Question",{"text":112,"@type":113},"Post-pregnancy breast cancer often has a poor prognosis and risk can persist for up to a decade. Later-life pregnancies further increase this clinical challenge, especially as maternal age rises.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does cabergoline affect breast cancer outcomes after pregnancy in mice?",{"text":117,"@type":113},"A single post-pregnancy dose of cabergoline delays tumor onset and reduces breast cancer incidence in Brca1/P53-deficient mice. It is associated with accelerated postlactational involution.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports cabergoline as a preventive strategy in humans?",{"text":121,"@type":113},"A retrospective cohort study in women showed a markedly lower incidence of post-pregnancy breast cancer in those treated with cabergoline compared with a control group.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335966,1790843630,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Universidad de Salamanca-CSIC. IBSAL  \nUniversidad de Salamanca-CSIC. IBSAL  \nUniversidad de Salamanca-CSIC. IBSAL  \nUnitat de Suport a la Recerca Metropolitana Sud, Fundació Institut Universitari per a la recerca al'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), L'Hospitalet de LL [https://orcid.org/0000-](https://orcid.org/0000-)[ ](https://orcid.org/0000-)0003-2891-099X  \nUnitat de Suport a la Recerca- IDIAP Jordi Gol. Direcció d'Atenció Primà ria Costa de Ponent, Institut Català de la Sal ut  \nUniversidad Complutense Madrid [https://orcid.org/0000-0001-5357-7178](https://orcid.org/0000-0001-5357-7178)  \nCancer Research Center (CIC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Cientí¦cas (CSIC) and University of Salamanca (USAL) [https://orcid.org/0000-0003-1015-9923](https://orcid.org/0000-0003-1015-9923)  \nCancer Research Center (IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Cienti¦cas & University of Salamanca [https://orcid.org/0000-0002-0984-9946](https://orcid.org/0000-0002-0984-9946)  \nServicio de Citometría, Departamento de Medicina, Biomedical Research Networking Centre on Cancer CIBER-CIBERONC (CB16/12/00400), Institute of Health Carlos III, and Instituto de Biolog  \nUniversity of Salamanca [https://orcid.org/0000-0002-0007-7230](https://orcid.org/0000-0002-0007-7230)  \nDepartamento de Ciencias Biomédicas y del Diagnóstico. Universidad de Salamanca.  \nUniversidad de Salamanca. IBSAL.  \nThe Medical Research Council Cancer Unit, University of Cambridge  \nCancer Science Institute of Singapore [https://orcid.org/0000-0002-6876-2672](https://orcid.org/0000-0002-6876-2672)  \nLawrence Berkeley National Laboratory [https://orcid.org/0000-0001-9320-6021](https://orcid.org/0000-0001-9320-6021)  \nLawrence Berkeley National Lab [https://orcid.org/0000-0002-3773-6818](https://orcid.org/0000-0002-3773-6818)  \nInstituto de Biología Molecular y Celular del Cá ncer (IBMCC-CIC)  \nCentro Nacional de Investigaciones Oncológicas (CNIO)  \nSpanish National Cancer Research Centre  \nSpanish National Cancer Research Centre (CNIO), Madrid  \nDepartamento de Cirugía, Universidad de Salamanca  \nDepartment of Surgery. University of Salamanca  \n 􀂦   \nUniversidad de Salamanca-CSIC. IBSAL  \nCabergoline, Breast Cancer Prevention, Post-Pregnancy Breast Cancer, Brca1/P53-De¦cient Mice, Postlactational Involution, Chemoprevention.  \n February 5th, 2024  \n [https://doi.org/10.21203/rs.3.rs-3854490/v1](https://doi.org/10.21203/rs.3.rs-3854490/v1)  \n 􀁱 􀅏 This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License  \n There is  Competing Interest.  \nPost-pregnancy breast cancer often carries a poor prognosis, posing a major clinical challenge. The increasing trend of later-life pregnancies exacerbates this risk, highlighting the need for effective chemoprevention strategies. Current options, limited to selective estrogen receptor modulators, aromatase inhibitors, or surgical procedures, offer limited e¨ cacy and considerable side effects. Here, wereport that cabergoline, a dopaminergic agonist, reduces the risk of breast cancer post-pregnancy in a Brca1/P53-de¦cient mouse model, with implications for human breast cancer prevention. We show th at a single dose of cabergoline administered post-pregnancy signi¦cantly delayed the onset and reduced the incidence of breast cancer in Brca1/P53-de¦cient mice. Histological analysis revealed a notable acceleration in post-lactational involution over the short term, characterized by increased apoptosis and altered gene expression related to ion transport. Over the long term, histological changes in the mammary gland included a reduction in the ductal component, decreased epithelial proliferation, and a lower presence of recombinant Brca1/P53 target cells, which are precursors of tumors. These changes serve as indicators of reduced breast cancer susceptibility. Additionally, RNA sequencing identi¦ed gene expression alterations associated with d","cbCainHpyIxWAAVD","https://ap.wps.com/l/cbCainHpyIxWAAVD","pdf",3337078,38,"English","# Background\n## Epidemiology of breast cancer after pregnancy\n# Cabergoline intervention and mechanisms\n## Effects on tumor onset and incidence\n## Histological and molecular changes\n## RNA sequencing findings\n# Translational evidence in humans\n## Retrospective cohort results\n# Implications for prevention strategy\n## Enhancing postlactational involution","[{\"question\":\"Why is post-pregnancy breast cancer prevention important?\",\"answer\":\"Post-pregnancy breast cancer often has a poor prognosis and risk can persist for up to a decade. Later-life pregnancies further increase this clinical challenge, especially as maternal age rises.\"},{\"question\":\"How does cabergoline affect breast cancer outcomes after pregnancy in mice?\",\"answer\":\"A single post-pregnancy dose of cabergoline delays tumor onset and reduces breast cancer incidence in Brca1/P53-deficient mice. It is associated with accelerated postlactational involution.\"},{\"question\":\"What evidence supports cabergoline as a preventive strategy in humans?\",\"answer\":\"A retrospective cohort study in women showed a markedly lower incidence of post-pregnancy breast cancer in those treated with cabergoline compared with a control group.\"}]","Cabergoline as a Novel Strategy for Post-Pregnancy Breast Cancer Prevention in Mice and Human | PDF",1790012974,96]